TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31083659

Group type: EXPERIMENTAL
Intervention: Knowledge of alcohol use among family physicians
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Knowledge of alcohol use among older professionals
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Knowledge of alcohol use among resident trainers
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Advice for reducing alcohol use by nurses
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Advice for reducing alcohol use by female professionals
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Advice for reducing alcohol use by professionals aged 46 to 55
Number of subjects: 1760
Study: 30290629

Group type: EXPERIMENTAL
Intervention: Gel cushion
Number of subjects: 75

Group type: COMPARATOR
Intervention: Foam cushion
Number of subjects: 75
Study: 26767313

Group type: EXPERIMENTAL
Intervention: ColoWrap (external abdominal compression device)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sham device (control)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: ColoWrap (external abdominal compression device) in patients with BMI 30-40 kg/m(2)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Sham device (control) in patients with BMI 30-40 kg/m(2)
Number of subjects: 350
Study: 23871316

Group type: EXPERIMENTAL
Intervention: Oral and maxillofacial surgeon
Number of subjects: 746
Study: 22002111

Group type: EXPERIMENTAL
Intervention: Intraprostatic injection of epinephrine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intraprostatic injection of saline solution (placebo)
Number of subjects: 23
Study: 19967669

Group type: EXPERIMENTAL
Intervention: 1-site phacotrabeculectomy
Number of subjects: 169

Group type: COMPARATOR
Intervention: 2-site phacotrabeculectomy
Number of subjects: 169
Study: 18261506

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled‐release (12.5‐25 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11575418

Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane at end‐tidal concentration 1‐1.5% (group I, n=20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Target‐controlled infusion (TCI) of propofol at target concentration 2‐5 microg ml(‐1) (group P, n=18)
Number of subjects: 38
Study: 9932224

Group type: EXPERIMENTAL
Intervention: Home strip-analysis for all children
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Biological tests before clinical symptoms
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Screening tests
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Recognition of increased risk
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Coping with disease recurrence
Number of subjects: 131
Study: 8060926

Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg twice daily for 4 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo washout for 3 days
Number of subjects: 7
Study: 30982860

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) at 800 kcal/d
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Weight maintenance dietary (WMD) intervention with different glycemic loads
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Baseline AMY1 CN
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Interaction analyses between AMY1 CN and nutrient intake
Number of subjects: 761
Study: 29286032

Group type: EXPERIMENTAL
Intervention: Continuous braided suture (Group I)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Bidirectional knotless barbed sutures (Group II)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 302
Study: 26246480

Group type: EXPERIMENTAL
Intervention: Prophylactic oral steroid administration
Number of subjects: 360

Group type: COMPARATOR
Intervention: Endoscopic local steroid injection
Number of subjects: 360
Study: 23831870

Group type: EXPERIMENTAL
Intervention: Single dose of rifampin (600 mg)
Number of subjects: 12
Study: 21685823

Group type: EXPERIMENTAL
Intervention: New ultrahigh-speed (UHS) 25-gauge system
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard 25-gauge vitrectomy system
Number of subjects: 120
Study: 19401528

Group type: EXPERIMENTAL
Intervention: 13‐cis RA/alpha tocopherol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 13‐cis RA
Number of subjects: 75

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined treatment (13‐cis RA and 13‐cis RA/alpha tocopherol)
Number of subjects: 75
Study: 16775717

Group type: EXPERIMENTAL
Intervention: Monitoring of internal thoracic impedance (ITI)
Number of subjects: 265
Study: 15301627

Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 0
Study: 12577389

Group type: EXPERIMENTAL
Intervention: Infantile umbilical paste (IUP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Compound Aspirin (APC)
Number of subjects: 220
Study: 9359049

Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole (up to 0.84 mg/kg over 10')
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (up to 10 mcg/kg/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no pharmacological stress)
Number of subjects: 60
Study: 8000787

Group type: EXPERIMENTAL
Intervention: Leptospirosis vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation with Staphylococcus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneous NBT test
Number of subjects: 0
Study: 29624530

Group type: EXPERIMENTAL
Intervention: Point-of-care gastric ultrasound
Number of subjects: 40
Study: 28535815

Group type: EXPERIMENTAL
Intervention: TAU + iABM
Number of subjects: 213

Group type: COMPARATOR
Intervention: TAU + placebo condition
Number of subjects: 213

Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 213
Study: 25464237

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 125
Study: 23240711

Group type: EXPERIMENTAL
Intervention: Alcohol infusion (target breath alcohol concentration = 0.06 g/dl)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Alcohol infusion
Number of subjects: 295
Study: 22022215

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ethyl chloride vapocoolant spray
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (baseline pain assessment)
Number of subjects: 41
Study: 19691847

Group type: EXPERIMENTAL
Intervention: Temporary fracture fixation with fixateur externe and defined secondary definitive treatment (DCO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary reamed nailing (early total care)
Number of subjects: 0
Study: 16968876

Group type: EXPERIMENTAL
Intervention: Self-reported health-related quality of life (HRQOL)
Number of subjects: 391
Study: 15614996

Group type: EXPERIMENTAL
Intervention: Phase locking value (PLV)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mean spectral coherence
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combination of phase synchronization measures with alpha power spectral density estimates
Number of subjects: 3

Group type: COMPARATOR
Intervention: Power densities in alpha, beta1, beta2, and 8-30 Hz frequency bands
Number of subjects: 3
Study: 11761499

Group type: EXPERIMENTAL
Intervention: Intercessory prayer group
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Intercessory prayer group (high-risk)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control group (high-risk)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Intercessory prayer group (low-risk)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control group (low-risk)
Number of subjects: 799
Study: 9250464

Group type: EXPERIMENTAL
Intervention: Hyperfiltering IDDM patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 38
Study: 8068482

Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant IFN alpha‐2b
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3711577

Group type: EXPERIMENTAL
Intervention: 1% tropicamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of 1% tropicamide and 2.5% phenylephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31377992

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Biliopancreatic Diversion (BPD)
Number of subjects: 16
Study: 29424121

Group type: EXPERIMENTAL
Intervention: Increased donation frequency
Number of subjects: 30
Study: 26856620

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: APM (subgroup analysis)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Sham surgery (subgroup analysis)
Number of subjects: 146
Study: 23847009

Group type: EXPERIMENTAL
Intervention: Active Treatment (AT)
Number of subjects: 47
Study: 22235841

Group type: EXPERIMENTAL
Intervention: Formoterol 9 μg via Turbuhaler®
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg via Diskus®
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo via Turbuhaler® and Diskus®
Number of subjects: 109
Study: 20178542

Group type: EXPERIMENTAL
Intervention: Catheter removal on 1st postoperative day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Catheter removal on 4th postoperative day
Number of subjects: 200
Study: 18827613

Group type: EXPERIMENTAL
Intervention: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim without BNP7787 (Group A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim with BNP7787 (Group B)
Number of subjects: 151
Study: 16408240

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous positive airways pressure therapy (CPAP)
Number of subjects: 0
Study: 14671142

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study: 10798794

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loprazolam (2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 9275691

Group type: EXPERIMENTAL
Intervention: Osmosis chemotherapy (5-FU)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (radical resection alone)
Number of subjects: 160
Study: 2000831

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SeMet) 200 micrograms Se/d
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selenate 200 micrograms Se/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (no added selenium)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (SeMet)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Selenate
Number of subjects: 33
Study: 6227078

Group type: EXPERIMENTAL
Intervention: Streptotriad
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iodochlorhydroxyquinoline combinations, neomycin, phthalsulphathiazole, furazolidone, bismuth salicylates
Number of subjects: 0
Study: 31273416

Group type: EXPERIMENTAL
Intervention: hTEE
Number of subjects: 550

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 550
Study: 28852205

Group type: EXPERIMENTAL
Intervention: Probiotics (Bio-25; Supherb)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 100
Study: 26762482

Group type: EXPERIMENTAL
Intervention: Topical 2% rebamipide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment with rebamipide)
Number of subjects: 40
Study: 24583430

Group type: EXPERIMENTAL
Intervention: Combination therapy (5-15 mg/day of prednisolone and 6 mg/week of methotrexate)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 17
Study: 23071826

Group type: EXPERIMENTAL
Intervention: Inclusion of Korean trials in Cochrane reviews
Number of subjects: 742

Group type: COMPARATOR
Intervention: Cochrane acupuncture reviews (existing trials)
Number of subjects: 742
Study: 21059430

Group type: EXPERIMENTAL
Intervention: Hemoglobin level <120 g/L
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Hemoglobin level 120 to 139 g/L
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Hemoglobin level 140 to 159 g/L
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Hemoglobin level >160 g/L
Number of subjects: 746
Study: 17331806

Group type: EXPERIMENTAL
Intervention: 21-mm circular stapler
Number of subjects: 200

Group type: COMPARATOR
Intervention: 25-mm circular stapler
Number of subjects: 200
Study: 16158206

Group type: EXPERIMENTAL
Intervention: Crohn disease
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis
Number of subjects: 129
Study: 12434609

Group type: EXPERIMENTAL
Intervention: Bolus thermodilution cardiac output (BCO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous thermodilution cardiac output (CCO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Esophageal echo-Doppler ultrasonography (ED-CO)
Number of subjects: 24
Study: 10599988

Group type: EXPERIMENTAL
Intervention: [1‐(13)C]KIC infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: [5,5,5‐2H3]KIC infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: [1‐(13)C]KIC
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: [5,5,5‐2H3]KIC
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: [phenyl‐2H5]phenylalanine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: KIC tracer extracted by the splanchnic bed
Number of subjects: 7
Study: 8560998

Group type: EXPERIMENTAL
Intervention: 200 micrograms misoprostol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1663282

Group type: EXPERIMENTAL
Intervention: 4-drug combination of 7-10 mg/kg rifabutin, 5 mg/kg isoniazid, 20 mg/kg ethambutol and 100 mg clofazimine
Number of subjects: 50
Study: 6136959

Group type: EXPERIMENTAL
Intervention: High dose isosorbide dinitrate in combination with nadolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High dose nifedipine in combination with nadolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nadolol alone and in combination with isosorbide dinitrate or nifedipine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High dose nifedipine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate in combination with nadolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Isosorbide treatment periods
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both isosorbide dinitrate and nifedipine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 19
Study: 30484683

Group type: EXPERIMENTAL
Intervention: Adjustable Fortification (AF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Targeted Fortification (TF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Fortification (SF)
Number of subjects: 60
Study: 28674765

Group type: EXPERIMENTAL
Intervention: AC-T (doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 201

Group type: COMPARATOR
Intervention: TAC (triplet chemotherapy)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: AC-T
Number of subjects: 201

Group type: COMPARATOR
Intervention: TAC
Number of subjects: 201
Study: 26433116

Group type: EXPERIMENTAL
Intervention: Targeted temperature of 33 °C
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Targeted temperature of 36 °C
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group (STEMI)
Number of subjects: 278
Study: 25045824

Group type: EXPERIMENTAL
Intervention: GS-4774 (10, 40, or 80 yeast units)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GS-4774 (80 yeast units)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GS-4774
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GS-4774 (10YU: 45%; 40YU: 35%; 80YU: 74%)
Number of subjects: 60
Study: 22744970

Group type: EXPERIMENTAL
Intervention: α(1)‐adrenoreceptor blockade with prazosin (0.05 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 18
Study: 19204511

Group type: EXPERIMENTAL
Intervention: Autonomous control of oxygen concentration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study: 17651596

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 31
Study: 15061656

Group type: EXPERIMENTAL
Intervention: Standard micronutrient supplementation in patients under long term parenteral nutrition
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group of fifty eight blood donors
Number of subjects: 41
Study: 11785713

Group type: EXPERIMENTAL
Intervention: 5-day course of ranitidine bismuth citrate 400 mg bid, clarithromycin 500 mg bid, and tinidazole 500 mg bid
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 10-day course of omeprazole 20 mg bid plus amoxycillin 1 g bid for the first 5 days, and omeprazole 20 mg bid, clarithromycin 500 mg bid and tinidazole 500 mg bid for the remaining 5 days
Number of subjects: 131
Study: 9408064

Group type: EXPERIMENTAL
Intervention: Cyclical oral clodronate with calcium supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Calcium supplementation alone
Number of subjects: 27
Study: 7690542

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 3896664

Group type: EXPERIMENTAL
Intervention: 300 mg pirazolac in the morning and 600 mg at night
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 450 mg pirazolac given morning and evening
Number of subjects: 24

Group type: COMPARATOR
Intervention: Overall assessment by 23 patients
Number of subjects: 24
Study: 31320345

Group type: EXPERIMENTAL
Intervention: Textured insole (n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Smooth insole (n=35)
Number of subjects: 70
Study: 29143534

Group type: EXPERIMENTAL
Intervention: Lithium-based treatment
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Quetiapine-based treatment
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Decreased activation
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Subsyndromal manic symptoms
Number of subjects: 303
Study: 26825311

Group type: EXPERIMENTAL
Intervention: Smartphone Airtraq(®) system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Airtraq(®) laryngoscope
Number of subjects: 30
Study: 24643430

Group type: EXPERIMENTAL
Intervention: Continuous exercise (CE)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interval exercise (IE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 15
Study: 23867841

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg daily for 6 months)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 212
Study: 20645525

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% lotion
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2141
Study: 17551088

Group type: EXPERIMENTAL
Intervention: Nurse-directed smoking cessation intervention (n = 38)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group received smoking cessation literature (n = 30)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nurse-directed intervention (n = 38)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Total sample (n = 68)
Number of subjects: 68
Study: 16613886

Group type: EXPERIMENTAL
Intervention: eSET (elective single embryo transfer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DET (double embryo transfer)
Number of subjects: 0
Study: 14644854

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 10892660

Group type: EXPERIMENTAL
Intervention: isosorbide-5-mononitrate (5-ISMN)
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 8831326

Group type: EXPERIMENTAL
Intervention: Atracurium 300 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium 500 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mivacurium 150 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mivacurium 250 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium 60 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Smaller doses of each drug
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Larger doses of each drug
Number of subjects: 50
Study: 1595430

Group type: COMPARATOR
Intervention: 3D FLASH examination
Number of subjects: 61

Group type: COMPARATOR
Intervention: 3D MP RAGE examination
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Standard examination (Sagittal T1-weighted spin echo, axial low flip angle gradient echo)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 3D FLASH and 3D MP RAGE examinations
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Single enhanced 3D T1-weighted imaging sequence
Number of subjects: 61
Study: 7448140

Group type: EXPERIMENTAL
Intervention: Extended contact lens wear for 18 weeks
Number of subjects: 45
Study: 31907860

Group type: EXPERIMENTAL
Intervention: Tailored triple therapy (TATT)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Traditional bismuth-containing quadruple therapy (TRBQT)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Tailored bismuth-containing quadruple therapy (TABQT)
Number of subjects: 467